Related Experiment Video
Updated: Aug 17, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Research advance on molecular and cellular biology of small cell lung cancer]
Fu-Yun Ji1, Gui-Sheng Qian, Gui-Jun Huang
1Institute of Respiratory Disease, Xinqiao Hospital, The Third Military Medical University, Chongqing, 400037, PR China.
Abstract:
Various genetic mutations and biologic alterations occur during cancerization, which promote the malignant development of tumors. Multiple genes are involved in and cooperated with the occurrence and development of small cell lung cancer (SCLC). SCLC manifests early and frequent metastasis as well as ultimate poor response to chemotherapy. New therapies for SCLC based on understanding of molecular and cellular mechanism of transformation are needed. SCLC is associated with multiple chromosomal abnormalities, the most common of which is chromosome 3p deletion, as well as abnormal oncogenes and tumor suppressor genes. Along with the genetic alterations, SCLC overexpresses various cell surface receptors, such as receptor tyrosine kinase (RTKs), G-protein-coupled receptors, integrins, and so on. Some activated downstream molecules, such as phosphatidylinositol 3'kinase, would serve as good candidates for therapeutic targets.
Insights
Small cell lung cancer (SCLC) involves genetic mutations and chromosomal abnormalities, leading to early metastasis and poor chemotherapy response. Targeting molecular pathways like receptor tyrosine kinases (RTKs) offers new therapeutic strategies for SCLC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Small cell lung cancer (SCLC) is characterized by early metastasis and resistance to conventional chemotherapy.
- Tumorigenesis in SCLC involves complex genetic mutations and biological alterations.
- Understanding the molecular mechanisms of SCLC is crucial for developing effective treatments.
Purpose:
- To review the genetic mutations, chromosomal abnormalities, and molecular alterations in small cell lung cancer (SCLC).
- To identify potential therapeutic targets based on the molecular landscape of SCLC.
Summary:
- SCLC development is driven by multiple cooperating genes and chromosomal abnormalities, notably chromosome 3p deletion.
- SCLC exhibits overexpression of cell surface receptors, including receptor tyrosine kinases (RTKs) and G-protein-coupled receptors.
- Activated downstream signaling molecules, such as phosphatidylinositol 3'-kinase, represent promising therapeutic targets for SCLC.
Impact:
- Highlights the need for novel SCLC therapies informed by molecular and cellular mechanisms.
- Identifies specific molecular targets, including RTKs and phosphatidylinositol 3'-kinase, for potential drug development in SCLC.
- Provides a foundation for precision medicine approaches in treating small cell lung cancer.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...